文献速递神经肿瘤

新诊断低级别胶质瘤中MGMT启动子甲基化水平可预测复发时超突变

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
PubMed 文献 · Neuro Oncol · 2020-01-01

研究利用定量深度测序检测37例接受替莫唑胺(TMZ)治疗的低级别胶质瘤(LGG)患者初发和复发肿瘤组织的MGMT启动子甲基化水平,发现复发时出现超突变的患者初发肿瘤甲基化水平显著更高(45.7% vs 34.8%,P=0.027),且该水平可在单变量和多变量模型中预测复发超突变。

要点

  • 复发时超突变患者初发肿瘤MGMT启动子甲基化水平显著高于未超突变者(45.7% vs 34.8%,P=0.027)。
  • 初发肿瘤MGMT启动子甲基化水平可在单变量和多变量模型中预测复发超突变。
  • MGMT启动子甲基化水平可能是指导LGG患者监测和治疗决策的潜在生物标志物。

核心结论

  • MGMT启动子甲基化水平是预测LGG患者复发时超突变的潜在生物标志物,可 informing 临床管理包括监测和治疗决策。

研究设计与样本

  • 研究纳入37例接受替莫唑胺(TMZ)治疗的低级别胶质瘤(LGG)患者,采集初发肿瘤和复发后组织标本共109份。
  • 采用定量深度测序检测MGMT启动子甲基化,用甲基化芯片验证测序方法,RNA测序评估甲基化与基因表达关系,外显子组测序确定超突变状态。

主要发现

  • 复发时发生超突变的患者初发肿瘤MGMT启动子甲基化水平为45.7%,未发生超突变者为34.8%,差异有统计学意义(P=0.027)。
  • 初发肿瘤甲基化水平可在单变量模型以及纳入患者年龄和分子亚型的多变量模型中预测复发超突变。

临床怎么用

  • 作者认为MGMT启动子甲基化水平可作为潜在生物标志物,通过预测复发超突变风险来 informing LGG患者的临床管理,包括监测和治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emerging data suggest that a subset of patients with diffuse isocitrate dehydrogenase (IDH)-mutant low-grade glioma (LGG) who receive adjuvant temozolomide (TMZ) recur with hypermutation in association with malignant progression to higher-grade tumors. It is currently unclear why some TMZ-treated LGG patients recur with hypermutation while others do not. MGMT encodes O6-methylguanine-DNA methyltransferase, a DNA repair protein that removes cytotoxic and potentially mutagenic lesions induced by TMZ. Here, we hypothesize that epigenetic silencing of MGMT by promoter methylation facilitates TMZ-induced mutagenesis in LGG patients and contributes to development of hypermutation at recurrence. METHODS: We utilize a quantitative deep sequencing assay to characterize MGMT promoter methylation in 109 surgical tissue specimens from initial tumors and post-treatment recurrences of 37 TMZ-treated LGG patients. We utilize methylation arrays to validate our sequencing assay, RNA sequencing to assess the relationship between methylation and gene expression, and exome sequencing to determine hypermutation status. RESULTS: Methylation level at the MGMT promoter is significantly higher in initial tumors of patients that develop hypermutation at recurrence relative to initial tumors of patients that do not (45.7% vs 34.8%, P = 0.027). Methylation level in initial tumors can predict hypermutation at recurrence in univariate models and multivariate models that incorporate patient age and molecular subtype. CONCLUSIONS: These findings reveal a mechanistic basis for observed differences in patient susceptibility to TMZ-driven hypermutation. Furthermore, they establish MGMT promoter methylation level as a potential biomarker to inform clinical management of LGG patients, including monitoring and treatment decisions, by predicting risk of hypermutation at recurrence.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Mathur R, Zhang Y, Grimmer MR, et al. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro Oncol. 2020. PMID: 32166314. doi:10.1093/neuonc/noaa059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。